CAR-T Cell Therapy in Istanbul: Revolutionary Cancer Treatment
CAR-T cell therapy represents one of the most significant advances in cancer treatment in decades. Istanbul's JCI-accredited hematology centers offer all major CAR-T products for blood cancers at 60-70% lower cost than the UK, with dedicated CAR-T units and experienced teams managing this complex treatment.
How much does CAR-T cell therapy cost in Istanbul?
CAR-T cell therapy costs $80,000–$150,000 in Istanbul depending on the product and indication. This compares to £250,000–£400,000 in the UK, where NHS access is limited and waiting times can be months. The cost includes T-cell collection, manufacturing, lymphodepletion chemotherapy, infusion, and 4-6 weeks of monitoring.
How CAR-T cell therapy works
CAR-T therapy is a personalized treatment. Your T-cells are collected through leukapheresis (a blood filtering process), sent to a manufacturing facility where they are genetically engineered to express a chimeric antigen receptor (CAR) targeting cancer cells, expanded to hundreds of millions of cells, and infused back into you after lymphodepletion chemotherapy.
The engineered T-cells recognize and destroy cancer cells expressing the target antigen (CD19 for B-cell cancers, BCMA for myeloma). Unlike chemotherapy, CAR-T cells can persist in the body for years, providing ongoing protection against relapse.
Available CAR-T products in Istanbul
Istanbul centers offer: axicabtagene ciloleucel (Yescarta) for DLBCL and follicular lymphoma, tisagenlecleucel (Kymriah) for ALL and DLBCL, idecabtagene vicleucel (Abecma) for multiple myeloma, and ciltacabtagene autoleucel (Carvykti) for multiple myeloma. The choice of product depends on your cancer type, prior treatments, and eligibility criteria.
Managing CAR-T side effects in Istanbul
The main risks of CAR-T therapy are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Istanbul's CAR-T units have dedicated protocols for managing these side effects, including tocilizumab for CRS and corticosteroids for ICANS. Patients are monitored 24/7 during the first 2-4 weeks after infusion.
CAR-T vs bone marrow transplant: which is right for you?
For relapsed/refractory ALL and DLBCL, CAR-T therapy has largely replaced salvage chemotherapy followed by allogeneic BMT as the preferred treatment. CAR-T avoids the risks of graft-versus-host disease and does not require a donor. Istanbul's tumor boards evaluate each patient individually to determine the optimal approach.
How to access CAR-T therapy in Istanbul
Send your pathology report, treatment history, and current disease status to our coordination team. Istanbul's hematology tumor board will assess your eligibility for CAR-T therapy and provide a treatment plan within 48-72 hours. T-cell collection can begin within 1-2 weeks of approval.
